Scilex Holding Co (SCLX) Stock Price & Analysis
Scilex Holding Co (SCLX) fell 1.28% to USD 6.95 as of June 10, 2026 at 13:32 UTC, according to Nexqual real-time market data.
SCLX last closed at USD 7.04; the session ranged USD 6.95–6.95 on volume of 871 shares. Market capitalization is $48.88M, with a 52-week range of USD 4.2–34.27 (NCM). Source: Nexqual, June 10, 2026 at 13:32 UTC.
Key Statistics (as of June 10, 2026 at 13:32 UTC)
| Price | USD 6.95 |
|---|---|
| Change | ▼ 1.28% (down) |
| Previous Close | USD 7.04 |
| Open | USD 6.95 |
| Day Range | USD 6.95 – 6.95 |
| 52-Week Range | USD 4.2 – 34.27 |
| Volume | 871 shares |
| Market Cap | $48.88M |
| Exchange | NCM |
Technical Analysis (SCLX)
Nexqual's technical model rates SCLX "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of June 10, 2026 at 13:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.75 (neutral) |
| vs SMA50 | Below (USD 7.28) |
| MACD | -0.08 (negative) |
Analyst Ratings (SCLX)
Wall Street analysts rate SCLX "None", per Nexqual as of June 10, 2026 at 13:32 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (SCLX)
| Next Earnings Date | 2026-03-12 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -1.17 vs est -0.47 ▼ miss |
| 2025-09-30 | USD -21.29 vs est -0.41 ▼ miss |
| 2025-06-30 | USD -7.42 vs est -0.91 ▼ miss |
| 2025-03-31 | USD -1.73 vs est -0.01 ▼ miss |
Source: Nexqual, June 10, 2026 at 13:32 UTC.
Financials & Fundamentals (SCLX)
| Total Revenue | $33.86M |
|---|---|
| Revenue Growth (YoY) | +72.10% |
| Gross Margin | +59.65% |
| Operating Margin | -373.49% |
| Profit Margin | +0.00% |
| Current Ratio | 0.08 |
| Total Cash | $3.36M |
| Total Debt | $106.36M |
| Free Cash Flow | $5.99M |
Source: Nexqual, June 10, 2026 at 13:32 UTC.
Financial Health Score (SCLX)
Nexqual rates Scilex Holding Co's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 13:32 UTC.
| Growth | Critical — Revenue -47% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $106M debt |
| Cash Flow | Strong — FCF $6M, 20% margin |
| Efficiency | Mixed — No data |
Ownership (SCLX)
| Insider Ownership | +17.56% |
|---|---|
| Institutional Ownership | +13.11% |
| Shares Outstanding | 7.03M |
| Float | 5.19M |
| Short % of Float | +4.13% |
Source: Nexqual, June 10, 2026 at 13:32 UTC.
Leadership (SCLX)
Scilex Holding Co is led by Henry H. Ji (age 61), CEO, President & Executive Chairman, per Nexqual as of June 10, 2026 at 13:32 UTC.
| CEO, President & Executive Chairman | Henry H. Ji (age 61) |
|---|---|
| Senior VP, CFO, COO, Corporate Secretary & Director | Stephen Ma (age 52) |
Major Backers & Investors (SCLX)
Notable institutional backers of Scilex Holding Co include Armistice Capital, LLC, Renaissance Technologies, Xtx Topco Ltd, according to Nexqual as of June 10, 2026 at 13:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 3.51% |
| Renaissance Technologies | 0.43% |
| Xtx Topco Ltd | 0.27% |
| Ashton Thomas Private Wealth, LLC | 0.21% |
| Morgan Stanley | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.68% |
| BlackRock | 1.59% |
| State Street | 0.42% |
| Northern Trust | 0.18% |
Source: Nexqual, June 10, 2026 at 13:32 UTC.
From Scilex Holding Co's Latest SEC 10-K Filing (filed 2026-04-10)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System ("FAERS").
Partnerships
- We acquired certain rights to GLOPERBA and the exclusive license to use the trademark "GLOPERBA®", pursuant to a License and Commercialization Agreement we entered into with RxOmeg Therapeutics LLC (a/k/a Romeg Therapeutics, LLC) ("Romeg"), dated as of June 14, 2022, which agreement was subsequently amended on January 16, 2025 (such agreement, as so amended, the "Romeg License Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SMNR | Semnur Pharmaceuticals Inc. | USD 3.1 | ▼ 38% |
| CELU | Celularity Inc. | USD 0.73 | ▼ 10.1% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.96 | ▼ 1.51% |
| SPRC | SciSparc Ltd. | USD 8.92 | ▼ 14.4% |
| OCEA | Ocean Biomediacal, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 13:32 UTC. This page is informational and not investment advice.